Research and Development of Cannabinoid Pharmaceuticals in Accordance with United States Food and Drug Administration (FDA) Regulatory Pathways. Nexien BioPharma operates in strict compliance with United States Drug Enforcement Administration (DEA) licensed pharmaceutical clinical research organizations (CRO's), contract manufacturing partners (CDMO's), and prestigious academic research institutions.
Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries. Our intent is that any medications we develop will be physician prescribed.
Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries. Our intent is that any medications we develop will be physician prescribed.
Services
Nexien BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.
Nexien has an expanding intellectual property portfolio of exclusive licensed technology, provisional patents, and certain allowed patents, for the use of cannabinoids as pharmaceutical API's for the treatment of targeted medical conditions.Nexien also has an exclusive license to a patented drug delivery mechanism for the use of cannabinoids in human and veterinary applications.
Nexien has an expanding intellectual property portfolio of exclusive licensed technology, provisional patents, and certain allowed patents, for the use of cannabinoids as pharmaceutical API's for the treatment of targeted medical conditions.Nexien also has an exclusive license to a patented drug delivery mechanism for the use of cannabinoids in human and veterinary applications.
This website is not an offer to sell any securities. Offers can be only be made to accredited investors in jurisdictions where the offer or sale can legally be made. This website contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.
For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements.Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements.
For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements.Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements.
At Nexien BioPharma we have built a trusted group of advisors that work to guide us in our corporate growth. Co-chair, Friedrich-Baur Institute, Germany's major national center for Neuromuscular Diseases. Director of Interdisciplinary Center for Neuromuscular Disorder at Ludwig Maximillian University.
Reviews
Be the first to review Nexien BioPharma.
Write a Review
